Background: Non-palpable splenomegaly in patients with polycythemia vera (PV) has seldom been addressed. In this retrospective study, we evaluated non-palpable, volumetric splenomegaly defined based on age- and body surface area (BSA)–matched criteria in patients with PV diagnosed according to the 2016 World Health Organization diagnostic criteria.

Methods: Patients with PV who underwent abdominal computed tomography (CT) and who had palpable splenomegaly at diagnosis from January 1991 to December 2020 at Chungnam National University Hospital were enrolled. The spleen volume of each patient was determined by volumetric analysis of abdominal CT and adjusted for the patient's age and BSA. Then the degree of splenomegaly was classified as no splenomegaly, borderline volumetric splenomegaly, overt volumetric splenomegaly, or palpable splenomegaly.

Results: Of the 87 PV patients enrolled, 15 (17.2%) had no splenomegaly, whereas 17 (19.5%), 45 (51.7%), and 10 (11.5%) had borderline volumetric, overt volumetric, and palpable splenomegaly, respectively. The degree of splenomegaly did not affect the cumulative incidence of thrombotic vascular events (10-year incidence: 7.7%, 0%, 22.3%, and 50.7%, respectively, \( P = 0.414 \)). By contrast, splenomegaly tended to adversely affect myelofibrotic transformation (10-year cumulative incidence: 0%, 0%, 7.1%, and 30.3%, respectively, \( P = 0.062 \)). Moreover, the cumulative incidence of myelofibrotic transformation was significantly higher in patients with overt volumetric or palpable splenomegaly than those with no or borderline volumetric splenomegaly (10-year OS: 100%, 78.6%, 71.7%, and 51.9%, respectively, \( P = 0.021 \)). Overall survival (OS) differed among patients with different degrees of splenomegaly (15-year OS: 100%, 78.6%, 71.7%, and 51.9%, respectively, \( P = 0.021 \)).

Conclusion: The degree of splenomegaly, including volumetric splenomegaly, based on age- and BSA-matched reference spleen volumes at diagnosis reflects disease progression in PV patients. Therefore, volumetric splenomegaly should be evaluated at the time of diagnosis and taken into consideration when predicting the prognosis of patients with PV.

Keywords: Polycythemia Vera; Spleen; Computed Tomography; Splenomegaly; Myelofibrosis; Survival
INTRODUCTION

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by increased production of red blood cells independent of the mechanism that normally regulates erythropoiesis. This disorder has a number of clinical characteristics in common with the other MPNs essential thrombocythemia (ET) and primary myelofibrosis (PMF), including an origin in hematopoietic stem cells, constitutive activation of hematopoiesis with overproduction of morphologically normal blood cells, extramedullary hematopoiesis, and transformation to bone marrow (BM) failure with myelofibrosis or acute leukemia.1

Splenomegaly is a clinical manifestation of MPNs and is most prominent in PMF.2,3 Palpable splenomegaly has been reported in 20–30% of patients with ET4-6 and has an even higher incidence in patients with PV at diagnosis.7,8 Palpable splenomegaly was previously one of the diagnostic criteria for PV.9 However, it is now just one of the additional criteria for a diagnosis of post-PV myelofibrosis,10 which indicates that splenomegaly is a sign of the advanced phase of this disorder. Non-palpable, imaging-based volumetric splenomegaly has also been studied in terms of diagnosis or prognostic significance in patients with MPN.11-14 The results, however, are lacking consistency and even difficult to interpret, most likely due to the arbitrary definition of the splenomegaly. This obstacle is inevitable because of the considerable variation in spleen size among individuals according to sex, age, and anthropometric parameters.15-18 This variation complicates the definition of volumetric splenomegaly. At present, palpable splenomegaly is not common in patients with PV,19-21 probably because of early detection facilitated by the wide application of health examination, a lowering of the diagnostic thresholds for hemoglobin and hematocrit levels,22 and the widely used driver gene mutation tests. Radiological volumetric analysis of spleen size is now readily available. However, non-palpable splenomegaly in patients with PV has seldom been addressed.

In this retrospective study, we evaluated non-palpable, volumetric splenomegaly defined based on age- and body surface area (BSA)–matched criteria at the time of diagnosis in patients with PV defined according to the 2016 World Health Organization (WHO) diagnostic criteria.22

METHODS

Patients
The medical records of patients with PV who underwent abdominal computed tomography (CT) at diagnosis and who had palpable splenomegaly at diagnosis between January 1991 and December 2020 at Chungnam National University Hospital were reviewed. Diagnoses of patients with MPN made prior to 2017 were revised according to the 2016 WHO diagnostic criteria. All laboratory data and BM specimens generated at the time of the initial diagnosis were reviewed and reexamined through the collaboration of a hematologist and a hematologic pathologist. Of the 133 patients who had previously been diagnosed with ET, 10 (7.5%) were re-diagnosed with PV based on hemoglobin and/or hematocrit levels and BM findings. Phlebotomy and hydroxyurea were prescribed according to standard treatment guidelines. Low-dose aspirin (100 mg daily) was prescribed to prevent thrombosis, except in patients who were at high risk of bleeding.
Driver gene mutation analysis

JAK2V617F was detected by polymerase chain reaction (PCR) and Sanger sequencing (before 2010) and allele-specific real-time quantitative PCR (after 2010). The JAK2 mutation in exon 12 was tested by PCR and Sanger sequencing.

CT

CT was performed with various scanners and techniques, but most images were obtained from the following multi-detector CT scanners: SOMATOM Sensation 16, SOMATOM Sensation 64, SOMATOM Definition Edge, and SOMATOM Definition Flash (all from Siemens Medical Solutions, Forchheim, Germany). The scanning parameters were as follows: section thickness, 3.0–5.0 mm; field of view, 304–360 mm; tube current-time product, 144–486 mAs; peak voltage, 100–120 kVp. After the acquisition of unenhanced scans, contrast-enhanced scans were performed. In total, 1.2–1.5 mL nonionic contrast material (iopromide [370 mg iodine/mL], Ultravist 370; Bayer Healthcare, Berlin, Germany) per kilogram of body weight was usually injected into the patient’s antecubital vein at a rate of 3–4 mL/s with a power injector. A bolus-tracking technique was used to optimize the timing of the arterial phase scan. Late portal phase images were obtained 70–80 seconds after contrast injection. A 20 mL flush of normal saline solution was administered immediately after contrast injection. Most axial CT images were reconstructed with a section thickness of 3 mm.

Volumetric analysis

Measurement of spleen volume was performed independently in a blind manner by two radiologists, through a consensus approach, using axial portal venous phase images. The Philips Multi-Modality Tumor Tracking application in IntelliSpace Portal version 10 (Philips Health Systems, Andover, MA, USA) was used to perform three-dimensional semi-automated quantitative assessment of spleen volume. The Philips Multi-Modality Tumor Tracking application allows researchers to define a lesion by identifying a region of interest (ROI) using either a manual or semi-automatic segmentation tool. The radiologists initiated volume segmentation manually by clicking on the spleen, then performing smart ROI threshold segmentation. They checked each section to determine whether any areas of the spleen were incorrectly excluded or included, and the incorrectly measured parts were semi-automatically edited using the software’s editing tool. Finally, spleen volume was calculated automatically.

Definition of splenomegaly

Reference spleen volumes based on age and BSA were adopted from a previous study (Supplementary Table 1). The study described normal spleen volumes of Japanese adults according to sex, age, and anthropometric parameters. The spleen volume of each patient was adjusted for the patient’s age and BSA, and then the degree of splenomegaly was classified as follows: no splenomegaly, spleen volume less than the mean plus 2 SD of the reference volume based on both age and BSA; overt volumetric splenomegaly, spleen volume greater than the mean plus 3 SD of the reference volume based on both age and BSA; borderline volumetric splenomegaly, a spleen volume between no splenomegaly and overt splenomegaly; or palpable splenomegaly, spleen palpable below the left costal margin (Supplementary Table 2).

Definitions of thrombotic and hemorrhagic events

Thrombotic events indicate cerebrovascular (ischemic stroke, transient ischemic attack, and venous sinus thrombosis), coronary (acute coronary syndrome and stable angina), splanchnic, and peripheral thromboembolism. A hemorrhagic event was defined as any acute bleeding that required a transfusion of red blood cells or hospitalization. The thrombotic or
hemorrhagic events in this study included all events that occurred before, at the time of, and after diagnosis.

**Statistical analysis**
Descriptive data are presented as means ± standard deviations, medians (ranges), or percentages. The categorical variables were analyzed with the chi-square test, Fisher's exact test, or the Kruskal–Wallis test as appropriate and the continuous variables were analyzed with Student's t-test. Pearson correlation analyses were used to define the correlations between spleen volume and various parameters. The cumulative incidence of thrombosis and myelofibrotic transformation was obtained with the Fine and Gray model, with death serving as a competing risk, and analyzed with the Gray equality test. Risk factors for myelofibrotic transformation were analyzed using the Fine and Gray regression model, with death serving as a competing risk. Overall survival (OS) was defined as the time from PV diagnosis to death due to any cause. Survival was estimated with the Kaplan–Meier method and analyzed with the log-rank test. Risk factors for OS were analyzed using the Cox regression model. Statistical analyses were performed with SPSS (ver. 24.0; IBM, Armonk, NY, USA) or SAS Studio (SAS Institute, Cary, NC, USA). In all analyses, $P < 0.05$ was taken to indicate statistical significance.

**Ethics statement**
The present study protocol was reviewed and approved by the Institutional Review Board of Chungnam National University Hospital (No. 2020-10-053). The need for informed consent was waived because of the retrospective nature of the analysis.

**RESULTS**

**Patient characteristics**
During the study period, 125 patients were newly diagnosed with PV. Palpable splenomegaly was noted in 10 (8.0%) patients, and it tended to be less common in recent years (Fig. 1). Of the 125 PV patients, 84 (67.2%) underwent abdominal CT at diagnosis. Of the 41 patients who did not undergo abdominal CT, 3 had palpable splenomegaly. Thus, a total of 87 patients were enrolled in the study (Supplementary Fig. 1). The majority (94.2%) of the 87 patients were diagnosed with PV after 2000. The study population had a male:female ratio of 1.5:1, had a median age of 64 years (range, 18–86 years), and was followed for a median of 4.5 years (range, 0.2–20.5 years). JAK2V617F and JAK2 exon 12 mutation were detected in 74 (92.5%) of 80 patients examined and 3 (3.8%) of 65 patients examined, respectively. Cytoreductive therapy and phlebotomy were prescribed for 73 (83.9%) and 83 (95.4%) patients, respectively.

![Incidence of splenomegaly over time in patients with polycythemia vera.](https://jkms.org/article-templates/figure/figure-1.png)

**Fig. 1.** Incidence of splenomegaly over time in patients with polycythemia vera.
Most patients were placed on low-dose aspirin. Thrombotic and hemorrhagic vascular events occurred in 29 (33.3%) and 12 (13.8%) patients, respectively, before, at the time of, or after the diagnosis of PV (Table 1).

### Spleen volume

Of the 87 PV patients, 15 (17.2%) had no splenomegaly at diagnosis. Borderline volumetric, overt volumetric, and palpable splenomegaly were found in 17 (19.5%), 45 (51.7%), and 10 (11.5%) patients, respectively (Table 1). Spleen volume was significantly positively correlated with lactate dehydrogenase (LDH) level ($r = 0.227$, $P = 0.042$) and tended to be positively related to white blood cell (WBC) count ($r = 0.209$, $P = 0.055$) and monocyte count ($r = 0.210$, $P = 0.059$) at diagnosis. Spleen volume was not correlated with hemoglobin level, platelet count, or JAK2 V617F burden at diagnosis (Supplementary Fig. 2).

### Comparison of patients with PV according to splenomegaly status

Clinical features were compared according to the degree of splenomegaly (i.e., no, borderline volumetric, overt volumetric, and palpable splenomegaly). There were no differences in age or sex distribution according to the degree of splenomegaly. WBC count ($P = 0.002$),

| Parameters                                      | Findings                                  |
|-------------------------------------------------|-------------------------------------------|
| Year of diagnosis                               |                                           |
| 1991–2000                                       | 5 (5.8)                                   |
| 2001–2010                                       | 28 (32.1)                                 |
| 2011–2020                                       | 54 (62.1)                                 |
| Age, yr, median (range)                         | 64 (18–86)                                |
| Sex, male                                       | 52 (59.8)                                 |
| Palpable splenomegaly                           | 10 (11.5)                                 |
| Laboratory findings                             |                                           |
| WBC, $\times 10^9$/L                            | 14.9 ± 6.0                                |
| Monocyte, $\times 10^9$/L                       | 6.9 ± 3.9                                 |
| Hemoglobin, g/dL                                | 18.3 ± 2.5                                |
| Platelet, $\times 10^9$/L                       | 474.7 ± 275.8                             |
| LDH, $\times$UNL                                | 1.5 ± 0.6                                 |
| Driver gene mutation                            |                                           |
| JAK2V617F                                       | 74/80 (92.5)                              |
| JAK2 exon12 mutation                            | 3/65 (3.8)                                |
| Comorbidity                                     |                                           |
| Diabetes mellitus                               | 22 (25.3)                                 |
| Hypertension                                    | 56 (64.4)                                 |
| Chronic kidney disease                          | 23 (26.4)                                 |
| Smoking                                         | 34 (39.1)                                 |
| Treatment                                       |                                           |
| Phlebotomy                                      | 83 (95.4)                                 |
| Cytoreductive therapy                           | 73 (83.9)                                 |
| Low-dose aspirin                                | 83 (95.4)                                 |
| Thrombotis$^a$                                  | 29 (33.3)                                 |
| Hemorrhage$^a$                                  | 12 (13.8)                                 |
| Spleen volumes/spleen volume, cm$^3$            |                                           |
| No splenomegaly                                 | 15 (28.7)/142.9 ± 53.2                    |
| Borderline volumetric splenomegaly             | 17 (19.5)/275.0 ± 73.3                    |
| Overt volumetric splenomegaly                  | 45 (51.7)/564.8 ± 230.8                   |
| Palpable splenomegaly                           | 10 (11.5)/1,459.2 ± 541.9$^b$             |
| Follow-up duration, yr, median (range)          | 4.5 (0.2–20.5)                            |

Values are presented as number (%) or mean ± standard deviation. WBC = white blood cell, LDH = lactate dehydrogenase, UNL = upper normal limit.

$^a$Overall events detected before, at the time of, and after diagnosis; $^b$Data are from the 7 patients who underwent abdomen computed tomography.
LDH level \((P=0.005)\), vitamin B12 level \((P=0.035)\), and positivity \((P=0.002)\) and burden \((P=0.047)\) of JAK2V617F tended to increase with the degree of splenomegaly. There were no differences in monocyte count, hemoglobin level, platelet count, or serum erythropoietin level or in the incidence of thrombotic or hemorrhagic vascular events according to the degree of splenomegaly. However, myelofibrotic transformation was more common in patients with advanced splenomegaly \((P=0.004)\) (Table 2). In Fine and Gray analyses, there were no differences in the cumulative incidence of thrombotic vascular events among patients with no, borderline volumetric, overt volumetric, or palpable splenomegaly (overall 10-year incidence: 20.1%, 35.3%, 39.7%, and 74.3%, respectively, \(P=0.310\); 10-year incidence after diagnosis: 7.7%, 0%, 22.3%, and 50.7%, respectively, \(P=0.414\) (Supplementary Fig. 3). Although thrombotic events tended to be more frequent in patients with palpable splenomegaly than in the other groups, in particular later in the clinical course, the difference did not reach statistical significance \((P=0.336)\) (data not shown). By contrast, splenomegaly tended to adversely affect myelofibrotic transformation (10-year cumulative incidence: 0%, 0%, 7.1%, and 30.3%, respectively, \(P=0.062\)). Moreover, the cumulative incidence of myelofibrotic transformation was significantly higher in patients with overt volumetric or palpable splenomegaly than those with no or borderline volumetric splenomegaly (10-year incidence: 0% vs. 10.3%, respectively; 15-year incidence: 0% vs. 26.3%, respectively, \(P=0.020\)) (Fig. 2). Survival differed among patients with no, borderline volumetric, overt volumetric, and palpable splenomegaly (15-year OS: 100%, 78.6%, 71.7%, and 51.9%, respectively, \(P=0.010\)) (Fig. 3A). Whereas survival was significantly worse in patients with volumetric splenomegaly than in patients with no splenomegaly, it was significantly better than in patients with palpable splenomegaly (15-year OS: 76.2%, 100%, and 51.9%, respectively, \(P=0.010\)) (Fig. 3B).

Table 2. Clinical features of polycythemia vera patients according to the degree of splenomegaly (N = 87)

| Parameters                        | No splenomegaly (n = 15) | Borderline volumetric splenomegaly (n = 17) | Overt volumetric splenomegaly (n = 45) | Palpable splenomegaly (n = 10) | \(P^a\) |
|-----------------------------------|--------------------------|---------------------------------------------|---------------------------------------|--------------------------------|--------|
| Age, yr, median (range)           | 62.0 (26–22)             | 73 (18–85)                                  | 62 (23–86)                            | 64 (18–86)                   | 0.264  |
| Sex, male:female                  | 7:8                      | 10:7                                        | 29:16                                 | 6:4                           | 0.685  |
| Laboratory findings               |                          |                                             |                                       |                               |        |
| WBC, \(\times 10^9/\text{L}\)     | 10.7 ± 2.5               | 13.8 ± 5.4                                  | 15.8 ± 5.7                            | 19.2 ± 8.4                    | 0.002  |
| Monocyte, \(\times 10^9/\text{L}\)| 0.6 ± 0.3                | 0.7 ± 0.4                                   | 0.6 ± 0.3                             | 1.1 ± 0.7                     | 0.150  |
| Hemoglobin, g/dL                  | 18.7 ± 1.7               | 17.4 ± 3.1                                  | 18.7 ± 2.5                            | 17.1 ± 1.4                    | 0.072  |
| Platelet, \(\times 10^9/\text{L}\)| 480.9 ± 418.4            | 450.1 ± 149.2                               | 504.2 ± 241.3                         | 389.3 ± 319.5                 | 0.292  |
| LDH, \(\times \text{UNL}\)        | 1.1 ± 0.3                | 1.3 ± 0.3                                   | 1.5 ± 0.5                             | 2.2 ± 0.8                     | 0.005  |
| Vitamin B12, pg/mL                | 796 ± 373                | 1,362 ± 493                                 | 1,768 ± 1,148                         | 1,623 ± 1,641                 | 0.035  |
| Serum EPO, mIU/mL                 | 2.7 ± 1.9                | 3.6 ± 3.0                                   | 6.0 ± 6.2                             | 4.7 ± 4.3                     | 0.193  |
| Gene mutation                     |                          |                                             |                                       |                               |        |
| JAK2V617F                         | 11/13 (84.6)             | 15/17 (88.2)                                | 42/44 (95.5)                          | 6/6 (100)                     | 0.002  |
| JAK2 exon12                        | 0/13 (0.0)               | 2/17 (11.8)                                | 1/44 (2.3)                            | 0/6 (0.0)                     | 0.022  |
| JAK2V617F VAF, %b                  | 47.8 ± 18.8              | 50.8 ± 26.4                                 | 64.1 ± 29.3                           | 69.7 ± 29.3                   | 0.047  |
| Comorbidity                        |                          |                                             |                                       |                               |        |
| Diabetes mellitus                 | 3 (20.0)                 | 6 (15.3)                                    | 12 (26.7)                             | 11 (0.0)                      | 0.483  |
| Hypertension                      | 13 (86.7)                | 8 (47.1)                                    | 31 (68.9)                             | 4 (40.0)                      | 0.037  |
| Chronic kidney disease            | 3 (20.0)                 | 3 (17.6)                                    | 18 (28.9)                             | 3 (30.0)                      | 0.556  |
| Smoking                           | 7 (46.7)                 | 6 (15.3)                                    | 12 (26.7)                             | 3 (37.5)                      | 0.843  |
| Thrombosis\(^c\)                  | 3 (20.0)                 | 6 (15.3)                                    | 14 (31.1)                             | 6 (60.0)                      | 0.210  |
| Hemorrhage\(^c\)                  | 1 (6.7)                  | 3 (17.6)                                    | 8 (17.8)                              | 0 (0.0)                       | 0.383  |
| Transformation                    |                          |                                             |                                       |                               |        |
| Myelofibrosis                     | 0 (0.0)                  | 0 (0.0)                                    | 5 (11.1)                              | 4 (40.0)                      | 0.004  |
| AML                               | 0 (0.0)                  | 0 (0.0)                                    | 1 (2.2)                               | 1 (10.0)                      | 0.335  |
| F/U, yr, median (range)           | 4.2 (0.4–15.0)           | 3.1 (0.2–14.3)                              | 4.4 (0.4–20.5)                        | 4.2 (0.2–15.7)                | 0.793  |

Values are presented as number (%) or mean ± standard deviation.

WBC = white blood cell, LDH = lactate dehydrogenase, UNL = upper normal limit, EPO = erythropoietin, VAF = variant allele frequency, AML = acute myeloid leukemia.

\(^a\chi^2\) or Kurskal-Wallis test; \(^b\)A total of 61 patients were examined; \(^c\)Overall events detected before, at the time of, and after diagnosis.
Fine and Gray regression analysis was performed to determine risk factors for myelofibrotic transformation. Degree of splenomegaly (i.e., no splenomegaly, volumetric splenomegaly, and palpable splenomegaly) (hazard ratio [HR], 7.75; 95% confidence interval [CI], 1.87–32.10; \( P = 0.005 \)) and abnormal karyotype (HR, 261.48; 95% CI, 7.57–9,036.32; \( P = 0.002 \)) at diagnosis were independent risk factors (Table 3). Degree of splenomegaly (HR, 6.70; 95% CI, 1.89–23.72; \( P = 0.004 \)) and abnormal karyotype (HR, 40.39; 95% CI, 3.41–493.33; \( P = 0.004 \)) at diagnosis also were independent risk factors for OS (Table 4).

**DISCUSSION**

In the present study, we defined non-palpable, volumetric splenomegaly based on age- and BSA-matched reference spleen volumes described previously.\(^17\) We divided non-palpable splenomegaly into borderline volumetric splenomegaly and overt volumetric splenomegaly in patients with PV at the time of diagnosis based on the assumption of a normal distribution of spleen volume according to age and body size. This classification was assumed to avoid the over- or underestimation of radiological splenomegaly likely in previous analyses that used universal criteria. This has been examined in our previous study of patients with ET and...
In that study, half of patients with ET had the normal spleen, whereas all patients with pre-PMF had borderline volumetric splenomegaly or a large spleen.

Palpable splenomegaly is a risk factor for thrombosis, myelofibrotic transformation, and mortality in patients with PV. Of the 125 PV patients in the present study cohort, only 10 (8.0%) had palpable splenomegaly, a much lower prevalence than those in previous reports. Moreover, the prevalence has decreased in recent years, whereas the incidence of PV has increased. On the other hand, only 15 (17.2%) of the 87 PV patients enrolled in the present study had a normal spleen. Thus, the majority of patients (82.8%) had borderline volumetric splenomegaly or larger spleen at diagnosis of PV. Pearson correlation analyses revealed that the spleen volume was positively correlated with WBC count and LDH level, both of which also tended to increase with the degree of splenomegaly. These findings are consistent with previous studies that indicate WBC count and LDH level are higher in MPN patients with palpable splenomegaly.

In the present study, the JAK2V617F allele burden increased with the degree of splenomegaly. The JAK2V617F allele burden was correlated with measurements of stimulated erythropoiesis (higher hematocrit level, lower mean cell volume, serum ferritin, and erythropoietin levels),
myelopoiesis (higher WBC count, neutrophil count, and serum LDH), and larger spleen size. In addition, the mutant allele burden is significantly related to the risk of developing myelofibrosis. Taken together, splenomegaly indicates a more advanced phase of the disease compared to the normal spleen.

Splenic extramedullary hematopoiesis is a major component of splenomegaly in patients with MPN, and myelofibrosis is a major factor leading to an enlarged spleen. In this context, it is understandable that the spleen volume is larger in patients with advanced PV. Accordingly, the suggestion that not only palpable splenomegaly but also volumetric splenomegaly may have similar implications is reasonable. In the present study, volumetric splenomegaly was not associated with thrombotic risk in patients with PV. Similar findings have been reported in patients with ET and pre-PMF. However, the cumulative incidence of myelofibrotic transformation was significantly higher in patients with overt volumetric or palpable splenomegaly than those with no or borderline volumetric splenomegaly. Furthermore, OS worsened as the degree of splenomegaly increased. Taken together, the degree of splenomegaly, including volumetric splenomegaly, reflects the progression of the disease, most likely toward myelofibrotic transformation.

The presence of leukocytosis, palpable splenomegaly at diagnosis or during follow-up, BM reticulin fibrosis, resistance/intolerance to hydroxyurea, in terms of the development of cytopenia and failure to reduce massive splenomegaly, and a long disease duration are associated with a greater risk for myelofibrotic transformation. In an international study of 1,545 patients with WHO-defined PV, the survival of the entire study cohort was adversely affected by older age, leukocytosis, venous thrombosis, and abnormal karyotype. In the present study, degree of splenomegaly and abnormal karyotype at the time of PV diagnosis were independent risk factors for both myelofibrotic transformation and OS. These results suggest that well-defined volumetric splenomegaly should be included as a prognostic indicator of PV.

Therefore, the results of this study need to be verified in a study on a larger number of patients.

In conclusion, the degree of splenomegaly, including volumetric splenomegaly based on age- and BSA-matched reference spleen volumes reflects disease progression in PV patients. Therefore, volumetric splenomegaly should be evaluated at the time of PV diagnosis and taken into consideration when predicting the prognosis of this disorder.

ACKNOWLEDGMENTS

The authors thank Dr. Hiroki Shirato and his colleagues for their kind permission to access age- and body surface area-matched reference spleen volumes.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Reference spleen volumes

Click here to view
### Supplementary Table 2
Classification and definition of splenomegaly

Click here to view

### Supplementary Fig. 1
Patient deposition.

Click here to view

### Supplementary Fig. 2
Correlations between spleen volume and various parameters in patients with polycythemia vera.

Click here to view

### Supplementary Fig. 3
Cumulative incidence of thrombotic vascular events according to the degree of splenomegaly in patients with polycythemia vera (PV). (A) Cumulative incidence of overall thrombotic events (before, at the time of, and after the diagnosis of PV). (B) Cumulative incidence of thrombotic events after the diagnosis of PV.

Click here to view

### REFERENCES

1. Spivak JL. Polycythemia vera. *Curr Treat Options Oncol* 2018;19(2):12.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

2. Mesa R. Myeloproliferative disorder-associated massive splenomegaly. *Clin Adv Hematol Oncol* 2008;6(4):278.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

3. Song MK, Park BB, Uhm JE. Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis. *Int J Mol Sci* 2018;19(3):E898.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

4. Hehlmann R, Jahn M, Baumann B, Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. *Cancer* 1988;61(12):2487-96.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

5. Jantunen R, Juvonen E, Ikvala E, Oksanen K, Antila P, Hormila P, et al. Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings. *Ann Hematol* 1998;77(3):101-6.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

6. Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. *Arch Intern Med* 2005;165(22):2651-8.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

7. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. *Am J Med* 2004;117(10):755-61.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

8. Xin CH, Xu JQ, Sui JR, Wang XL. Analysis on 71 patients with polycythemia vera. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2012;20(3):667-70.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)

9. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thromboctemia Vera Study Group. *Semin Thromb Hemost* 1997;23(4):339-47.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3346/jkms.2022.37.e87)
10. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. *Curr Hematol Malig Rep* 2009;4(1):33-40.

11. Carneskog J, Wadenvik H, Fjälling M, Kutti J. Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera. *Eur J Haematol* 1996;56(3):158-62.

12. Messinezy M, Macdonald LM, Nunan TO, Westwood NB, Chinn S, Pearson TC. Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: comparison with SPECT. *Br J Haematol* 1997;98(1):103-7.

13. Picardi M, Martinelli V, Ciancia R, Soscia E, Morante R, Sodano A, et al. Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. *Blood* 2002;99(11):4228-30.

14. Accurso V, Santoro M, Raso S, Contrino AD, Casimiro P, Piazza FD, et al. Splenomegaly impacts prognosis in essential thrombocytopenia and polycythaemia vera: a single center study. *Hematol Rep* 2019;11(4):8281.

15. Kaneko J, Sugawara Y, Matsui Y, Ohkubo T, Makuuchi M. Normal splenic volume in adults by computed tomography. *Hepatogastroenterology* 2002;49(48):1726-7.

16. Caglar V, Alkoc OA, Uygur R, Serdaroglu O, Ozen OA. Determination of normal splenic volume in relation to age, gender and body habitus: a stereological study on computed tomography. *Folia Morphol (Warsz)* 2014;73(3):331-8.

17. Harris A, Kamishima T, Hao HY, Kato F, Omatsu T, Onodera Y, et al. Spleenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with age, gender, and anthropometric parameters. *Eur J Radiol* 2010;75(1):e97-101.

18. Sprogøe-Jakobsen S, Sprogøe-Jakobsen U. The weight of the normal spleen. *Forensic Sci Int* 1997;88(3):215-23.

19. Kiritto K, Suzuki K, Miyamura K, Takeuchi M, Handa H, Okamoto S, et al. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythaemia vera with splenomegaly. *Int J Hematol* 2018;107(2):173-84.

20. Grieshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. *Ann Hematol* 2018;97(9):1591-600.

21. Song IC, Yeon SH, Lee MW, Ryu H, Lee HJ, Yun HJ, et al. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm. *Korean J Intern Med* 2021;36(5):1190-203.

22. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016;127(20):2391-405.

23. Lee MW, Yeon SH, Ryu H, Song IC, Lee HJ, Yun HJ, et al. Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis. *Int J Hematol* 2021;114(1):35-43.

24. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. *Blood Cancer J* 2017;7(12):662.

25. Bai J, Xue Y, Ye L, Yao J, Zhou C, Shao Z, et al. Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythaemia vera: a single center experience from China. *Int J Hematol* 2008;88(5):530-5.

26. Bai J, Ai L, Zhang L, Yang FC, Zhou Y, Xue Y. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. *Am J Hematol* 2015;90(12):1116-21.
27. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J 2015;5(11):e366.
PUBMED | CROSSREF

28. Mitra D, Kaye JA, Piccoro LT, Brown J, Reith K, Mughal TI, et al. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review. Cancer Med 2013;2(6):889-98.
PUBMED | CROSSREF

29. Wang J, Xu J, Gale RP, Xu Z, Li B, Qin T, et al. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis. Leuk Res 2014;38(10):120741.
PUBMED | CROSSREF

30. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007;21(9):1952-9.
PUBMED | CROSSREF

31. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21(9):1952-9.
PUBMED | CROSSREF

32. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24(9):1574-9.
PUBMED | CROSSREF

33. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011;35(2):177-82.
PUBMED | CROSSREF

34. Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, et al. Impact of JAK2V617F mutation burden on disease phenotype in Chinese patients with JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET). Int J Med Sci 2016;13(4):85-91.
PUBMED | CROSSREF

35. Kough RH. Idiopathic myelofibrosis with myeloid metaplasia of the spleen; a disease entity being recognized with increasing frequency. Med Times 1966;94(4):489-96.
PUBMED

36. Kirshner JJ, Goldberg J, Landaw SA. The spleen as a site of colony-forming cell production in myelofibrosis. Proc Soc Exp Biol Med 1980;165(2):279-82.
PUBMED | CROSSREF

37. Douay L, Laporte JP, Lefrancois G, Najman A, Dupuy-Montbrun MC, Lopez M, et al. Blood and spleen haematopoiesis in patients with myelofibrosis. Leuk Res 1987;11(8):725-30.
PUBMED | CROSSREF

38. Passamonti F, Mora B, Barraco D, Maffioli M. Post-ET and post-PV myelofibrosis: updates on a distinct prognosis from primary myelofibrosis. Curr Hematol Malig Rep 2018;13(3):173-82.
PUBMED | CROSSREF

39. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27(9):1874-81.
PUBMED | CROSSREF

https://doi.org/10.3346/jkms.2022.37.e87